HUP9903893A2 - Eljárás szívelégtelenségnek ciklopentánnal kondenzált heterogyűrűs endotelin-antagonistákkal történő kezelésére - Google Patents
Eljárás szívelégtelenségnek ciklopentánnal kondenzált heterogyűrűs endotelin-antagonistákkal történő kezeléséreInfo
- Publication number
- HUP9903893A2 HUP9903893A2 HU9903893A HUP9903893A HUP9903893A2 HU P9903893 A2 HUP9903893 A2 HU P9903893A2 HU 9903893 A HU9903893 A HU 9903893A HU P9903893 A HUP9903893 A HU P9903893A HU P9903893 A2 HUP9903893 A2 HU P9903893A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- heart failure
- atom
- oxo
- warm
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 title 2
- 102000002045 Endothelin Human genes 0.000 title 1
- 108050009340 Endothelin Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- -1 2-oxo-3H-1,2,3,5-oxathiadiazol-4- yl Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 208000009982 Ventricular Dysfunction Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 230000006815 ventricular dysfunction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
A találmány tárgya eljárás szívelégtelenségnek és ventrikulárisdiszfunkciónak meleg vérű állatban történő megelőzésére és/vagykezelésére, amelyre jellemző, hogy egy ilyen kezelést igénylő melegvérű állatnak egy (I) általános képletű endotelinantagonistának vagygyógyászatilag elfogadható sójának terápiásan hatásos mennyiségétadagolják, a képletben Ar1 és Ar2 jelentése egymástól függetlenül adott esetbenhelyettesített fenilcsoport, tienilcsoport, piridilcsoport,indolilcsoport, benzofuranilcsoport vagy dihidrobenzofuranilcsoport; R1, R2 és R3 jelentése egymástól függetlenül hidrogénatom,hidroxilcsoport vagy 1-6 szénatomos alkilcsoport, vagy R1 és R2 vagyR2 és R3 együtt egy vegyértékkötést képez; Y jelentése -CO-R4 általános képletű csoport[amelyben R4 jelentésehidroxilcsoport, aminocsoport, alkoxicsoport, mono- vagy dialkil-amino-csoport, alkil-szulfonil-amino-csoport vagy aril-szulfonil-amino-csoport, vagy aril-alkil-szulfonil-amino- csoport, amelyben azarilgyűrűn jelen lévő hidrogénatomo(ka)t adott esetben alkilcsoporthelyettesíti], SO3H csoport, PO3H2 csoport, tetrazol-5-il-csoport, 2-oxo-3H-1,2,3,5-oxatiadiazol-4-il-csoport vagy 5-oxo-4H-1,2,4-oxadiazol-3-il-csoport; és A jelentése olyan csoport, amely a szomszédos szén-szén kettőskötéssel együtt egy heteroaromás gyűrűt képez, amely a nitrogénatom,oxigénatom és a kénatom közül választott 1-4 heteroatomot tartalmaz ésadott esetben helyettesített. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1488296P | 1996-04-04 | 1996-04-04 | |
| PCT/US1997/003737 WO1997037665A1 (en) | 1996-04-04 | 1997-03-19 | Method of treating heart failure with endothelin antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9903893A2 true HUP9903893A2 (hu) | 2001-04-28 |
| HUP9903893A3 HUP9903893A3 (en) | 2001-05-28 |
Family
ID=21768326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9903893A HUP9903893A3 (en) | 1996-04-04 | 1997-03-19 | Method of treating heart failure with cyclopentane fused heterocyclic endothelin antagonists |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US5834483A (hu) |
| EP (1) | EP0906108B1 (hu) |
| JP (2) | JP3345891B2 (hu) |
| KR (1) | KR20000005178A (hu) |
| CN (1) | CN1215335A (hu) |
| AT (1) | ATE297739T1 (hu) |
| AU (1) | AU723351B2 (hu) |
| BG (1) | BG102716A (hu) |
| BR (1) | BR9708525A (hu) |
| CA (1) | CA2249330C (hu) |
| CZ (1) | CZ296098A3 (hu) |
| DE (1) | DE69733557T2 (hu) |
| EA (1) | EA003587B1 (hu) |
| EE (1) | EE9800315A (hu) |
| ES (1) | ES2241047T3 (hu) |
| HU (1) | HUP9903893A3 (hu) |
| IL (1) | IL126175A (hu) |
| IS (1) | IS4847A (hu) |
| NO (1) | NO984564L (hu) |
| NZ (1) | NZ331789A (hu) |
| PL (1) | PL329077A1 (hu) |
| SK (1) | SK130098A3 (hu) |
| TR (1) | TR199801988T2 (hu) |
| UA (1) | UA50761C2 (hu) |
| WO (1) | WO1997037665A1 (hu) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2249330C (en) | 1996-04-04 | 2005-08-09 | Banyu Pharmaceutical Co., Ltd. | Method of treating heart failure with endothelin antagonists |
| JPH11514676A (ja) * | 1996-08-09 | 1999-12-14 | メルク エンド カンパニー インコーポレーテッド | 立体選択的脱酸素化反応 |
| US6413979B1 (en) | 1998-01-21 | 2002-07-02 | Banyu Pharmaceutical Co., Ltd. | Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US20060089503A1 (en) * | 2002-12-27 | 2006-04-27 | Kaneka Corporation | Processes for producing optically active 2-thiomethyl-3-phenylpropionic acid derivative and for producing intermediate therefor |
| KR20180050427A (ko) | 2003-11-17 | 2018-05-14 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
| GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| JP2007529459A (ja) | 2004-03-17 | 2007-10-25 | ノバルティス アクチエンゲゼルシャフト | 治療に置けるレニン阻害剤の使用 |
| US20100040666A1 (en) | 2005-06-24 | 2010-02-18 | Hiroshi Azuma | Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent |
| AR080683A1 (es) | 2010-03-16 | 2012-05-02 | Novartis Ag | Composiciones farmaceuticas de aliskiren y metodos de administracion |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4971959A (en) * | 1987-04-14 | 1990-11-20 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
| GB9007762D0 (en) * | 1990-04-05 | 1990-06-06 | Beecham Group Plc | Novel compounds |
| US5565485A (en) * | 1993-03-19 | 1996-10-15 | Merck & Co., Inc. | Biphenyl compounds useful or endothelin antagonists |
| US5571813A (en) * | 1993-06-10 | 1996-11-05 | Beiersdorf-Lilly Gmbh | Fused pyrimidine compounds and their use as pharmaceuticals |
| ATE199151T1 (de) * | 1993-08-18 | 2001-02-15 | Banyu Pharma Co Ltd | Kondensierte heteroaromatische cyclopentenderivate mit endothelin- antagonistischer aktivität |
| US5389620A (en) * | 1993-08-18 | 1995-02-14 | Banyu Pharmaceutical Co., Ltd. | Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives |
| US5658943A (en) * | 1995-01-05 | 1997-08-19 | Warner-Lambert Company | Phenylalanine derivatives as endothelin antagonists |
| CA2249330C (en) * | 1996-04-04 | 2005-08-09 | Banyu Pharmaceutical Co., Ltd. | Method of treating heart failure with endothelin antagonists |
-
1997
- 1997-03-19 CA CA002249330A patent/CA2249330C/en not_active Expired - Fee Related
- 1997-03-19 BR BR9708525A patent/BR9708525A/pt not_active Application Discontinuation
- 1997-03-19 CZ CZ982960A patent/CZ296098A3/cs unknown
- 1997-03-19 JP JP53619497A patent/JP3345891B2/ja not_active Expired - Fee Related
- 1997-03-19 WO PCT/US1997/003737 patent/WO1997037665A1/en active IP Right Grant
- 1997-03-19 ES ES97914955T patent/ES2241047T3/es not_active Expired - Lifetime
- 1997-03-19 CN CN97193645A patent/CN1215335A/zh active Pending
- 1997-03-19 DE DE69733557T patent/DE69733557T2/de not_active Expired - Lifetime
- 1997-03-19 NZ NZ331789A patent/NZ331789A/xx unknown
- 1997-03-19 UA UA98105222A patent/UA50761C2/uk unknown
- 1997-03-19 EP EP97914955A patent/EP0906108B1/en not_active Expired - Lifetime
- 1997-03-19 HU HU9903893A patent/HUP9903893A3/hu unknown
- 1997-03-19 PL PL97329077A patent/PL329077A1/xx unknown
- 1997-03-19 EA EA199800889A patent/EA003587B1/ru not_active IP Right Cessation
- 1997-03-19 KR KR1019980707850A patent/KR20000005178A/ko not_active Application Discontinuation
- 1997-03-19 TR TR1998/01988T patent/TR199801988T2/xx unknown
- 1997-03-19 EE EE9800315A patent/EE9800315A/xx unknown
- 1997-03-19 AT AT97914955T patent/ATE297739T1/de not_active IP Right Cessation
- 1997-03-19 AU AU22025/97A patent/AU723351B2/en not_active Ceased
- 1997-03-19 IL IL12617597A patent/IL126175A/xx not_active IP Right Cessation
- 1997-03-19 SK SK1300-98A patent/SK130098A3/sk unknown
- 1997-03-26 US US08/824,848 patent/US5834483A/en not_active Expired - Fee Related
-
1998
- 1998-08-11 US US09/132,514 patent/US6087360A/en not_active Expired - Lifetime
- 1998-08-21 BG BG102716A patent/BG102716A/xx unknown
- 1998-09-15 IS IS4847A patent/IS4847A/is unknown
- 1998-09-30 NO NO984564A patent/NO984564L/no not_active Application Discontinuation
-
2000
- 2000-02-22 US US09/507,666 patent/US6380195B1/en not_active Expired - Fee Related
-
2001
- 2001-12-07 JP JP2001374870A patent/JP2002220337A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG128491A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
| HUP0200469A2 (hu) | Szulfamátszármazékok alkalmazása az impulzus kontrol zavarok kezelésére | |
| EA200801806A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| EA200100970A1 (ru) | Аминопроизводные как ингибиторы протеазы | |
| HUP0301120A2 (hu) | Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények | |
| DE69923849D1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
| YU69902A (sh) | Novi derivati piperazina | |
| ATE188472T1 (de) | 4-arylmethyloxymethyl piperidine als tachykinin antagonisten | |
| NO20021358D0 (no) | Alkylendiamin-substituerte heterocykler | |
| HUP9902471A2 (hu) | Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| DK0894084T3 (da) | Kanelsyrederivater og deres anvendelse som integrinantagonister | |
| CA2401812A1 (en) | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy | |
| MXPA04002423A (es) | Derivados de piperazina con actividad antagonista del receptor ccr1. | |
| DE60045508D1 (de) | Dalda-analoge und ihre verwendung | |
| UA66865C2 (uk) | Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти) | |
| NO990433L (no) | Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet | |
| DE69505968D1 (de) | Azolidindion-derivate und ihre anwendung als antihyperglykämika | |
| DE69924292D1 (de) | Pyrazol verbindungen und ihre verwendung | |
| UA35584C2 (uk) | Лікарський засіб для лікування або профілактики ішемії міокарда та спосіб лікування ішемії міокарда у ссавців | |
| SE9703414D0 (sv) | New compounds | |
| HUP9903893A2 (hu) | Eljárás szívelégtelenségnek ciklopentánnal kondenzált heterogyűrűs endotelin-antagonistákkal történő kezelésére | |
| MXPA03011466A (es) | Macrociclos utiles en tratamiento de enfermedades de alzheimer. | |
| ES2111930T3 (es) | Antagonistas del acido amp y procedimientos de tratamiento con la ayuda de estos. | |
| NO983178L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasaytisk preparat for behandling eller profylakse av menopausesymptomer |